Kongfei Li
YOU?
Author Swipe
View article: Anti-CD22 Calecheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azatabine in the Treatment of Mixed Phenotype Acute Leukemia: A Case Report
Anti-CD22 Calecheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azatabine in the Treatment of Mixed Phenotype Acute Leukemia: A Case Report Open
Mixed-phenotype acute leukemia (MPAL) is an unusual subtype of leukemia, which can contain more than 1 lineage-defining marker on a single blast population (biphenotypic) or 2 or more identifiable single-lineage leukemia populations (bilin…
View article: Primary refractory diffuse large B-cell lymphoma of the uterine cervix metastasizing to the kidney: A case report
Primary refractory diffuse large B-cell lymphoma of the uterine cervix metastasizing to the kidney: A case report Open
View article: RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells Open
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that necroptosis, a form of programmed cell death, contributed to the antil…
View article: Identification of potential biomarkers in myelodysplastic syndromes by weighted gene co-expression network analysis
Identification of potential biomarkers in myelodysplastic syndromes by weighted gene co-expression network analysis Open
MDS is characterized by great heterogeneity in clinical manifestations, cytogenetic and molecular biological manifestations, therapeutic options and efficacy. The lack of specific molecular mechanism discovery and effective targeted therap…
View article: All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex Open
View article: A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation Open
The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MD…
View article: High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia
High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia Open
Acute myeloid leukemia (AML) is a frequent malignancy in adults worldwide; identifying preferable biomarkers has become one of the current challenges. Given that COMMD7 has been reported associated with tumor progression in various …
View article: Tigecycline and homoharringtonine synergistically target myeloid leukemia cells by inhibiting mitochondrial translation through mTOR/4EBP1 pathway
Tigecycline and homoharringtonine synergistically target myeloid leukemia cells by inhibiting mitochondrial translation through mTOR/4EBP1 pathway Open
BackgroundTigecycline (TIG) is a tetracycline derivative antibiotic. Successive studies have shown that TIG is efficacious for the treatment of some solid tumors and hematological malignant diseases both in vivo and in vitro, and drug comb…
View article: Author response for "Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial"
Author response for "Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial" Open
Patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndrome (MDS) or higher-risk MDS have limited treatment options and poor prognosis. Our previous single-center study of decitabine followed by low dose idarubicin an…
View article: E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway
E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway Open
The DEAD/DEAH box helicase 11 (DDX11) plays vital roles in regulating the initiation of DNA replication. However, its precise function and regulation in hepatocellular carcinoma (HCC) have never been reported yet. In the current study, we …
View article: UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370
UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370 Open
View article: CBX2 is a functional target of miRNA let‐7a and acts as a tumor promoter in osteosarcoma
CBX2 is a functional target of miRNA let‐7a and acts as a tumor promoter in osteosarcoma Open
Osteosarcoma is the most common type of primary malignant tumor of skeletal with poor prognosis in children and adolescents. Accumulating evidence indicates that CBX2 is overexpressed in multiple human neoplasm and play a critical role in …
View article: High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition.
High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition. Open
In summary, these findings suggest the potential prognostic and therapeutic value of NNT-AS1/miR-142-5p/HMGA2 axis in CCA patients.
View article: Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis
Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis Open
Low miR-139 expression was related to poor prognosis in HCC and GBM, which could be regarded as a potential prognostic biomarker. However, its precise functional role in CRC still need to be further investigated through larger samples and …
View article: Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation Open
View article: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation Open